BIJUVA (estradiol and progesterone) by Mayne Pharma is estrogen receptor agonists [moa]. First approved in 2018.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
BIJUVA is an oral capsule combining estradiol and progesterone approved in 2018 for hormone replacement therapy in menopausal women. It works as an estrogen receptor agonist to alleviate vasomotor symptoms and other menopausal manifestations. The product represents a convenient single-capsule approach to combined hormone therapy.
Product is at peak commercial maturity with modest Part D claims; brand team is likely stable-sized and focused on market maintenance rather than aggressive growth initiatives.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
Worked on BIJUVA at Mayne Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
BIJUVA offers stable, maintenance-focused career opportunities in a peak-stage commercial product with modest market size but strong patent protection through 2032. Professionals joining this team should expect steady-state market management, compliance-heavy work, and preparation for generic LOE transition planning.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo